NIH Logo
February 24, 2017
Volunteers

Study on Depression, Repeated Doses of Ketamine Now Enrolling

Join a research study on depression. The purpose is to evaluate the rapid and sustained antidepressant effects of repeat doses of ketamine in the brain. Researchers want to learn how ketamine affects areas of the brain important in regulating mood and if there are unique signatures that could help predict who may respond to the drug. Also, investigators want to see if repeated doses of ketamine are safe and effective in treating the symptoms of depression. The study is enrolling eligible adults ages 18 to 65 with major depressive disorder. This inpatient study lasts 14-20 weeks. Procedures include a medication taper and drug-free period, taking repeated doses of the research drug, taking placebo, multiple brain imaging scans, transcranial magnetic stimulation and psychological testing. After completing the study, participants receive short-term follow-up care at NIH while transitioning back to a provider. There is no cost to participate. Compensation is provided. Study enrolls eligible participants from across the U.S. Travel arrangements are provided. Costs are covered by NIMH. To find out if you qualify, call 1-877-646-3644 (1-877-MIND-NIH), TTY 1-866-411-1010.

Patients with Leukemia Needed

NHLBI is testing if the two medications, pembrolizumab and decitabine, can be used to treat adult patients with relapsed/refractory AML (acute myeloid leukemia). Study-related medications, procedures and tests are at no cost. Travel may be reimbursed. For more information, call the Office of Patient Recruitment, 1-866-444-2214 (TTY 1-866-411-1010). Read about the study at http://go.usa.gov/x9PKv. Refer to study 17-H-0026.

Study Seeks Healthy Older Adults

Healthy older adults, ages 55-70, are invited to participate in an outpatient research study investigating the benefits of tart cherry and aroniaberry supplementation on vascular health. The goal of the study is to determine whether the supplements improve blood flow and blood vessel function that can affect your heart. Eligible participants must be medication-free and in good general health. The study will be carried out in an outpatient clinic and includes 7 visits over 3-4 months. Compensation for the study is provided. For more information, call 1-800-411-1222 (TTY 1-866-411-1010) and refer to study 15-NR-0085 or visit www.clinicaltrials.gov.

Patients with Kidney Disease Needed

An NIDDK team seeks patients for a research study. Doctors are conducting a study evaluating the safety of an investigational drug, ManNAc (N-acetyl-D-mannosamine monohydrate, IND: DEX-M74), in patients with the following kidney diseases: focal segmental glomerulosclerosis, membranous nephropathy, minimal change disease. Compensation is provided for participation. For more information, call 1-866-444-2214 (TTY 1-866-411-1010). Read more online at http://go.usa.gov/xkfT4. Refer to study 16-DK-0036.

Antidepressant Study Needs Volunteers

Depression, ketamine and alcohol researchers are evaluating rapid antidepressant effects in the brain. This inpatient study is enrolling eligible adults ages 21 to 65, who are free of other serious medical conditions, for 4-7 weeks as research participants. Procedures may include tapering off antidepressants, a medication-free period, 2 infusions of alcohol and 1 infusion of low-dose ketamine (an FDA-approved anesthetic) and 2 brain scans (MRI). There is no cost to participate. Compensation is provided. Study enrolls eligible participants from across the U.S. Travel arrangements provided and costs are covered by NIMH. After completing the study, participants receive short-term follow-up care at NIH while transitioning back to a provider. For more information, email moodresearch@mail.nih.gov, or call 1-877-MIND-NIH (1-877-646-3644), TTY 1-866-411-1222. Refer to protocol 14-M-0085, principal investigator Dr. Carlos Zarate, Jr.

Unipolar & Bipolar Depression Studies Recruiting

Studies are enrolling eligible participants ages 18-65 with unipolar or bipolar depression symptoms for a 2-3 month inpatient stay. Study compares ketamine, an experimental medication, to placebo and evaluates rapid reduction of depressive symptoms (within hours). For details, visit www.nimh.nih.gov/labs-at-nimh/join-a-study/index.shtml or call 1-877-MIND-NIH (1-877-646-3644), TTY 1-866-411-1010, email moodresearch@mail.nih.gov. Refer to protocol 04-M-0222.

back to top of page